Inzoboon 500mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts by targeting mitochondrial bioenergetics, improving insulin sensitivity, enhancing glucose-stimulated insulin secretion, and reducing hepatic glucose production. This multifaceted mechanism helps in achieving better glycemic control in patients inadequately managed with diet and exercise alone or in combination with other antidiabetic agents. Inzoboon is administered orally, typically once or twice daily as prescribed by a healthcare professional, with dosage adjustments based on renal function and therapeutic response. Clinical studies have demonstrated its efficacy in lowering HbA1c levels, fasting plasma glucose, and postprandial glucose, contributing to improved overall metabolic parameters. The safety profile of Imeglimin is favorable, with a low incidence of hypoglycemia when used as monotherapy or in combination with agents not associated with hypoglycemia. Common adverse effects may include mild gastrointestinal symptoms such as nausea or diarrhea, which are generally transient. Inzoboon should be used cautiously in patients with renal impairment and is contraindicated in cases of severe renal dysfunction. Regular monitoring of glycemic status and renal function is recommended during therapy to optimize treatment outcomes and minimize potential risks.